Kenvue Inc (KVUE) Stock Price, Quote & News

Company Profile

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and bod...

Industry: Household & Personal Products

Sector: Consumer Defensive

Phone: 908 874 1200

Website: www.kenvue.com

Address:

1 Kenvue Way, Summit, United States

Suite510 May. 11 at 11:01 PM

$ABT $JNJ $KVUE $SPX JNJ up next to get slammed 🤡 BUSINESS Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula

0 · Reply

Suite510 May. 11 at 6:17 PM

$ABT $JNJ $KVUE $SPX These Junk n Junk clowns 🤡 getting desperate, NOT a single talc trial win since March 2025 Ex-FDA Chief Says J&J Atty 'Spinning' Asbestos Definition A former U.S. Food and Drug Administration commissioner told an attorney for Johnson & Johnson she was "spinning" the definition of asbestos in an attempt to confuse a jury in a bellwether trial over claims the company's talc products caused three women's deaths from ovarian cancer.

0 · Reply

Synaptric May. 11 at 12:49 PM

Meanwhile, in the non-parabolic sectors of the market, many fine long-term pickings are merely at their 200-day moving average. $GE $JPM $SO $KVUE $FAST

0 · Reply

Suite510 May. 8 at 11:03 AM

$JNJ $KVUE $SPX $ABT baby issues 😂 'Do Not Use This Report': J&J Hid Asbestos Test, Jury Told Johnson & Johnson and a consultant it hired in the 1970s altered the conclusions of tests that found alarming levels of asbestos in the company's talc products before giving different results to the U.S. Food and Drug Administration, a former FDA commissioner told a Los Angeles jury Wednesday.

0 · Reply

IWontAskHowUrTradeGoing May. 8 at 10:57 AM

$KMB $KVUE and at what price because those earnings demand a premium

0 · Reply

Kylea1 May. 7 at 7:22 PM

$KVUE when’s this merger closing? $KMB

0 · Reply

TonyG6ix May. 7 at 3:56 PM

$KVUE still working it.

0 · Reply

Estimize May. 7 at 1:03 PM

$KVUE reported 0.32 EPS and 3,909 revenue for Q1. http://www.estimize.com/intro/kvue?chart=historical&metric_name=eps&utm_content=KVUE&utm_

0 · Reply

TragicRain May. 7 at 11:15 AM

$KVUE - Crushed earnings - but its trapped in lock with KMB for the merger - this should actually make KMB go up in price because they are buying all this beautiful earnings...

0 · Reply

StocktwitsEarnings May. 7 at 10:37 AM

$KVUE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.25 up 47.06% YoY • Reported revenue of $3.91B up 4.49% YoY

0 · Reply

Kenvue beats first-quarter estimates amid pending acquisition by Kimberly-Clark

KMB

2026-05-07T11:12:08.000Z - 6 days ago

Kenvue reports Q1 adjusted EPS 32c, consensus 26c

May 7, 2026, 6:30 AM EDT - 6 days ago

Kenvue Reports First Quarter 2026 Results

Apr 29, 2026, 6:45 AM EDT - 14 days ago

Kenvue Declares Quarterly Cash Dividend

Apr 26, 2026, 9:40 AM EDT - 16 days ago

This 5-Stock “Super Staples” Portfolio Yields Up To 11.3%

CAG CALM FLO KMB NOMD

Apr 23, 2026, 4:32 PM EDT - 19 days ago

Kenvue to Announce First Quarter 2026 Results on May 7, 2026

Apr 15, 2026, 10:01 AM EDT - 27 days ago

Kimberly-Clark Details Structure, Leadership Team Following Kenvue Deal

KMB

Apr 15, 2026, 9:52 AM EDT - 27 days ago

Kimberly-Clark retains Urdaneta as CFO of combined company after $40-billion Kenvue deal

KMB

2026-04-15T13:04:56.000Z - 27 days ago

Kimberly-Clark announces organizational structure after acquisition of Kenvue

KMB

Apr 15, 2026, 8:55 AM EDT - 27 days ago

Kimberly-Clark Announces Post-Closing Organizational Structure and Identifies Key Leadership

KMB

2026-04-15T10:40:06.000Z - 4 weeks ago

Kenvue price target lowered to $19 from $20 at Citi

2026-04-14T13:08:51.000Z - 4 weeks ago

Kenvue price target lowered to $18 from $19 at Barclays

Apr 13, 2026, 2:09 PM EDT - 4 weeks ago

Tylenol in pregnancy not linked with autism, Danish study finds

2026-04-07T18:45:14.000Z - 5 weeks ago

Kenvue Inc call volume above normal and directionally bullish

2026-04-07T11:09:21.000Z - 5 weeks ago

Kenvue price target lowered to $18 from $19 at UBS

Mar 6, 2026, 12:43 PM EST - 2 months ago

Tylenol use among women dropped after Trump tied it to autism

2026-03-06T10:52:41.000Z - 2 months ago

Kenvue price target raised to $19 from $18 at Barclays

2026-02-26T17:20:12.000Z - 2 months ago

Judge spurns Kenvue bid to dismiss Texas lawsuit over Tylenol, Reuters reports

Feb 26, 2026, 11:14 AM EST - 2 months ago

Judge rejects Kenvue bid to dismiss Texas lawsuit over Tylenol

2026-02-20T20:45:18.000Z - 2 months ago

Kenvue Inc call volume above normal and directionally bullish

2026-02-20T20:31:01.000Z - 2 months ago

Kenvue rumor highlighted in Betaville blog

2026-02-18T12:46:01.000Z - 2 months ago

Kenvue price target raised to $19 from $17 at UBS

2026-02-18T12:17:16.000Z - 3 months ago

Kenvue price target raised to $18 from $17 at Canaccord

2026-02-18T11:35:35.000Z - 3 months ago

Kenvue price target raised to $20 from $18 at Citi

Feb 17, 2026, 5:50 PM EST - 3 months ago

Kenvue to Cut 3.5% of Workforce Ahead of Kimberly-Clark Deal

Feb 17, 2026, 5:42 PM EST - 3 months ago

Kenvue beats quarterly estimates, announces job cuts amid Kimberly-Clark acquisition

KMB

2026-02-17T21:50:45.000Z - 3 months ago

Kenvue reports Q4 EPS 27c, consensus 22c

Feb 17, 2026, 4:45 PM EST - 3 months ago

Kenvue Reports Fourth Quarter and Full Year 2025 Results

2026-02-17T19:05:13.000Z - 3 months ago

Kenvue Inc options imply 3.7% move in share price post-earnings

Feb 4, 2026, 6:45 AM EST - 3 months ago

Kenvue to Announce Fourth Quarter and Full Year 2025 Results on February 17, 2026

2026-01-30T10:10:21.000Z - 3 months ago

Jefferies downgrades Kenvue with deal closer to completion

KMB

Jan 29, 2026, 9:27 AM EST - 3 months ago

Kimberly-Clark and Kenvue Shareholders Overwhelmingly Approve Kimberly-Clark's Acquisition of Kenvue

KMB

Jan 29, 2026, 9:00 AM EST - 3 months ago

Kenvue Transcript: AGM 2026

Jan 27, 2026, 6:40 AM EST - 3 months ago

Kimberly-Clark Posts Higher Profit Ahead of Kenvue Vote

KMB

Jan 16, 2026, 6:32 PM EST - 4 months ago

Paracetamol/Tylenol in pregnancy is safe, says research prompted by Trump autism claims

Jan 16, 2026, 10:00 AM EST - 4 months ago

ISS recommends shareholders approve Kimberly-Clark's planned Kenvue deal

KMB

Nov 17, 2025, 6:07 AM EST - 6 months ago

US appeals court to weigh reviving cases over Tylenol and autism

Nov 14, 2025, 12:42 PM EST - 6 months ago

Texas state judge won't block Kenvue from paying dividend, company lawyer says

Nov 14, 2025, 6:05 AM EST - 6 months ago

Judge to weigh if Texas AG can block Kenvue dividend over Tylenol

Nov 6, 2025, 8:06 AM EST - 6 months ago

Texas seeks to block Kenvue dividend amid Tylenol lawsuit

Nov 3, 2025, 10:00 PM EST - 6 months ago

The CEO Behind Kimberly-Clark's $40 Billion Gamble on Tylenol Maker

KMB

Nov 3, 2025, 7:11 PM EST - 6 months ago

Kenvue Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kenvue Inc. - KVUE

KMB

Nov 3, 2025, 6:40 PM EST - 6 months ago

Kimberly-Clark CEO talks Kenvue acquisition, calls Tylenol brand 'resilient'

KMB

Nov 3, 2025, 5:20 PM EST - 6 months ago

Kenvue's legal risks loom over planned acquisition by Kimberly-Clark

KMB

Nov 3, 2025, 5:15 PM EST - 6 months ago

S&P 500 Gains & Losses Today: Amazon Stock Jumps After OpenAI Deal; Kimberly-Clark Acquires Kenvue

AMZN KMB

Nov 3, 2025, 4:58 PM EST - 6 months ago

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kenvue Inc.

KMB

Nov 3, 2025, 4:39 PM EST - 6 months ago

Kimberly-Clark's $50 billion leap into health and beauty tests investor faith

KMB

Nov 3, 2025, 4:01 PM EST - 6 months ago

KVUE stock price: Kenvue soars 19% today, Kimberly-Clark deal offers a win after Trump Tylenol drama

KMB

Nov 3, 2025, 3:29 PM EST - 6 months ago

Explainer: Is Tylenol safe to take during pregnancy?

KMB

Nov 3, 2025, 12:37 PM EST - 6 months ago

Kenvue deal could double Kimberly-Clark stock's multiple: find out more

KMB

Nov 3, 2025, 12:01 PM EST - 6 months ago

Kimberly-Clark to buy Tylenol maker Kenvue in massive consumer merger

KMB

Nov 3, 2025, 11:40 AM EST - 6 months ago

Kimberly-Clark Is Buying Tylenol Maker Kenvue for Nearly $49B. Here's What You Need to Know

KMB

Nov 3, 2025, 11:18 AM EST - 6 months ago

Kimberly-Clark Buying Tylenol Maker Kenvue in $40 Billion Deal

KMB

Nov 3, 2025, 10:44 AM EST - 6 months ago

Kimberly-Clark buys Tylenol maker Kenvue in a cash and stock deal for $48.7 billion

KMB

Nov 3, 2025, 10:33 AM EST - 6 months ago

Activist Investors in Kenvue Faced Big Losses. Kimberly-Clark Saved the Day.

KMB

Nov 3, 2025, 9:57 AM EST - 6 months ago

Kimberly-Clark agrees to buy Tylenol owner Kenvue, creating consumer staples giant

KMB

Nov 3, 2025, 9:30 AM EST - 6 months ago

Another Big Earnings Week Ahead, KVUE Soars on KMB $48.7B Deal

Nov 3, 2025, 9:16 AM EST - 6 months ago

Kimberly-Clark to buy Tylenol maker Kenvue in landmark $40bn merger

KMB

Nov 3, 2025, 9:15 AM EST - 6 months ago

Kimberly-Clark Buys Embattled Tylenol Maker Kenvue In $48 Billion Deal

KMB

Nov 3, 2025, 8:40 AM EST - 6 months ago

Kimberly-Clark to acquire Tylenol owner Kenvue in $48.7 billion deal

KMB

Nov 3, 2025, 8:27 AM EST - 6 months ago

Kimberly-Clark to buy embattled Tylenol maker Kenvue in a deal valued at more than $48 billion

KMB

Nov 3, 2025, 8:24 AM EST - 6 months ago

Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark's $48.7-billion deal

KMB

Nov 3, 2025, 8:00 AM EST - 6 months ago

Kenvue Transcript: M&A Announcement

Nov 3, 2025, 7:49 AM EST - 6 months ago

Kimberly-Clark agrees to buy Kenvue in $48.7 billion deal, creating consumer staples giant

KMB

Suite510 May. 11 at 11:01 PM

$ABT $JNJ $KVUE $SPX JNJ up next to get slammed 🤡 BUSINESS Court upholds $495 million verdict against Abbott Laboratories in case over preterm infant formula

0 · Reply

Suite510 May. 11 at 6:17 PM

0 · Reply

Synaptric May. 11 at 12:49 PM

Meanwhile, in the non-parabolic sectors of the market, many fine long-term pickings are merely at their 200-day moving average. $GE $JPM $SO $KVUE $FAST

0 · Reply

Suite510 May. 8 at 11:03 AM

0 · Reply

IWontAskHowUrTradeGoing May. 8 at 10:57 AM

$KMB $KVUE and at what price because those earnings demand a premium

0 · Reply

Kylea1 May. 7 at 7:22 PM

$KVUE when’s this merger closing? $KMB

0 · Reply

TonyG6ix May. 7 at 3:56 PM

$KVUE still working it.

0 · Reply

Estimize May. 7 at 1:03 PM

$KVUE reported 0.32 EPS and 3,909 revenue for Q1. http://www.estimize.com/intro/kvue?chart=historical&metric_name=eps&utm_content=KVUE&utm_

0 · Reply

TragicRain May. 7 at 11:15 AM

$KVUE - Crushed earnings - but its trapped in lock with KMB for the merger - this should actually make KMB go up in price because they are buying all this beautiful earnings...

0 · Reply

StocktwitsEarnings May. 7 at 10:37 AM

$KVUE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.25 up 47.06% YoY • Reported revenue of $3.91B up 4.49% YoY

0 · Reply

DonCorleone77 May. 7 at 3:02 AM

$KVUE $TPR $USFD $U $PLNT Some notable companies reporting before tomorrow's open, with earnings consensus estimates: - McDonald's (MCD), consensus $2.74 - Howmet Aerospace (HWM), consensus $1.11 - Datadog (DDOG), consensus 51c - Zoetis (ZTS), consensus $1.62 - Becton Dickinson (BDX), consensus $2.77 - Kenvue (KVUE), consensus 26c - Tapestry (TPR), consensus $1.29 - US Foods (USFD), consensus 81c - Unity (U), consensus 24c - Planet Fitness (PLNT), consensus 63c - Warby Parker (WRBY), consensus 11c - Peloton (PTON), consensus 7c - TripAdvisor (TRIP), consensus (7c) - Shell (SHEL), consensus $2.21 - Six Flags (FUN), consensus ($2.74) - Papa John's (PZZA), consensus 37c .

0 · Reply

Suite510 May. 7 at 1:49 AM

$JNJ $KVUE $SPX 🤣😝

0 · Reply

Suite510 May. 7 at 1:48 AM

$JNJ $KVUE $SPX Rut Ro legal boat to sink again 🤣 Ex-FDA Chief Testifies 100s Of JNJ Docs Tie Asbestos To Talc A former U.S. Food and Drug Administration commissioner on Tuesday testified in a Los Angeles bellwether trial over claims JNJ talc products caused deadly ovarian cancer in three women, saying hundreds of internal company documents reveal the company knew for decades that its talc contained asbestos.

0 · Reply

CapitalMonk May. 4 at 9:13 PM

$KVUE Price: $17.15 (-1.61%) Trend: Bullish Market Bias (7D): Bullish Bias 📈 Expected Range: ±1.18% RSI: 44.0 | Momentum: Moderate Volume: -29.0% vs avg Volatility: 1.45% Support: $16.64 | Resistance: $17.83 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

Suite510 Apr. 30 at 2:27 AM

$JNJ $KVUE $SPX $SPY Whoops 😬 more talc trouble in London now, oh yea it’s safe lol A major legal case in which Johnson & Johnson (J&J) is accused of knowingly selling baby powder contaminated with asbestos, now involves 7,111 claimants.

0 · Reply

MHM7700 Apr. 27 at 7:54 PM

40% gains locked in on the $KVUE calls. Scaling out some here. https://www.stocktwits.com/MHM7700/message/651545063

0 · Reply

MHM7700 Apr. 27 at 6:51 PM

$KVUE 0501 17.5c $.261

0 · Reply

TwelveEggsInOneBasket Apr. 25 at 4:04 AM

$KVUE $KMB still one of my favorite blue chips. There arent many single stocks out there that provide the consistency and dividend rate. Selling calls + dividend.

0 · Reply

TonyG6ix Apr. 24 at 6:00 PM

$KVUE in it, have a couple of short puts expiring today.

0 · Reply

Candleclosekinghq Apr. 23 at 4:23 PM

$KVUE 17.5 CALL 04/24 @0.17 #KVUE

0 · Reply

Candleclosekinghq Apr. 23 at 4:18 PM

Watching $KVUE 17.5 CALL 04/24 SO close to being itm. Should go green quick for us

0 · Reply

25yrgold Apr. 22 at 7:11 PM

$KVUE

0 · Reply

Market Cap	32.97B
Revenue (ttm)	15.12B
Net Income (ttm)	1.47B
EPS (ttm)	N/A
PE Ratio	15.16
Forward PE	15.18
Profit Margin	9.72%
Debt to Equity Ratio	0.67

Volume	23,714,700
Avg Vol	20,572,027
Day's Range	N/A - N/A
Shares Out	1.92B
Stochastic %K	52%
Beta	0.55
Analysts	Sell
Price Target	$19.00